Skip to main content

Susana Otero Romero

-

Institutions of which they are part

Head of group
Epidemiology and Public Health
Vall Hebron Institut de Recerca
Allergology
General Hospital
Susana Otero Romero

Susana Otero Romero

Susana Otero Romero

Institutions of which they are part

Head of group
Epidemiology and Public Health
Vall Hebron Institut de Recerca
Allergology
General Hospital

-

-

Research lines

Clinical epidemiology of Multiple Sclerosis

To characterize the epidemiology of multiple sclerosis (MS) in Catalonia, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed.

Recently, and in collaboration with the Center of Multiple Sclerosis of Catalonia (Cemcat), we have set up a prospective registry of vaccination in patients with Immuno-Mediated Inflammatory Disease (IMID) who are candidates for biological treatment with the aim of evaluating vaccine immunogenicity and safety that will allow establishing the best vaccination strategy. In addition, we will study the prevalence and impact of comorbidity on Multiple Sclerosis prognosis.

IP: Susana Otero Romero

Projects

Caracterización de las infecciones y de su impacto en pacientes con Esclerosis Múltiple en la era de los tratamientos inmunosupresores de alta eficacia

IP: Susana Otero Romero
Collaborators: Imane Boutitah Benyaich, Blanca Borras Bermejo, Anna Falcó Roget, Mar Tintore Subirana, Ana Zabalza de Torres, Jesus Trejo Zahinos, Enrique Rodríguez Zafra
Funding agency: Instituto de Salud Carlos III
Funding: 115000
Reference: PI23/01654
Duration: 01/01/2024 - 31/12/2026

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

DRIVE

IP: Susana Otero Romero
Collaborators: Eva del Amo Moran, Constanza Olivares Castillo
Funding agency: The Innovative Medicines Initiative
Funding: 130847.5
Reference: DRIVE_IMI2-2021
Duration: 01/10/2021 - 30/09/2022

Measuring brand-specific influenza vaccine effectiveness

IP: Susana Otero Romero
Collaborators: Eva del Amo Moran, Magda Campins Martí, Cristina Andrés Vergés
Funding agency: The Innovative Medicines Initiative
Funding: 69562.5
Reference: DRIVE_IMI2-2019_SUBART11
Duration: 24/10/2019 - 24/10/2020

Related news

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.

A l'estudi hi participaran 200 persones voluntàries i es durà a terme a 10 hospitals espanyols, entre els quals Vall d’Hebron.

Related professionals

Adnoub Ovmaima el Haddouchi

Adnoub Ovmaima el Haddouchi

General Services and Infrastructure
Manager
Read more
Menyar Ben Jaballah

Menyar Ben Jaballah

Postdoctoral researcher
Diagnostic nanotools (DINA)
Read more
Vanessa Casares Rodríguez

Vanessa Casares Rodríguez

Research technician
Shock, Organ Dysfunction and Resuscitation
Read more
Nuria Santamaria Torner

Nuria Santamaria Torner

Tècnic/a Grau Superior
Unitat legal
Direcció Jurídica
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.